The recent addition to the list is, abiraterone- the CYP171A1 inhibitor which blocks androgen synthesis, approved for treatment of late stage, castrationresistant prostate cancer [48], crizotinib -inhibitor of the protein kinase ALK approved for the treatment of NSCLC patients with a pathogenic rearrangement of the ALK gene [49] and vemurafenib – inhibitor of BRAF kinase [50] for metastatic melanoma with the BRAF V600E mutation. Here, ALK is linked to prostate cancer.